Dr. Franz Rischard, DO
Internal Medicine (Internal Medicine Physician)
6200 N La Cholla Blvd
Tucson, AZ 85741
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 128
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
AZ license 3752
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 240
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 84 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 29 |
| Established patient office or other outpatient visit, 30-39 minutes | 19 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sildenafil Citrate Other prescribers in Tucson, AZ | 32 |
| Tadalafil | 27 |
| Opsumit (macitentan) | 24 |
| Uptravi (selexipag) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 24 payments worth $19,189 in total to this clinician.
| Merck Sharp & Dohme LLC | $18,417 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $615 |
| United Therapeutics Corporation | $157 |
| Consulting Fee | $16,935 |
|---|---|
| Travel and Lodging | $1,644 |
| Food and Beverage | $610 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $10,240 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Consulting Fee | $4,480 |
| Merck Sharp & Dohme LLC May 14, 2025 | Consulting Fee | $1,600 |
| Actelion Pharmaceuticals US, Inc. Dec 12, 2025 | Consulting Fee UPTRAVI · Cardiology | $615 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $422 |
| Merck Sharp & Dohme LLC Oct 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind | $410 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Travel and Lodging travel to Dallas, TX | $150 |
| Merck Sharp & Dohme LLC Oct 29, 2025 | Travel and Lodging travel to Chicago, IL | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $406,612 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Merck Sharp & Dohme LLC - A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510 - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186 - BAY 632521, RiOciguAt UseRs Registry The ROAR registry
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.